Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated biocatalysis platform designed to accelerate enzyme development for biomanufacturing. The platform combines computational enzyme engineering with practical process development, delivering AI-driven biocatalysis solutions that are predictable in silico and stable at industrial scale. This launch addresses a critical gap between identifying application opportunities and obtaining suitable enzymes, as traditional development methods struggle to meet the speed requirements of iterative product development.
AI brings critical value on three fronts: predicting enzyme candidates for specific biocatalytic reactions, designing enzymes constrained by process parameters rather than biological factors, and leveraging molecular features to anticipate process performance. These capabilities reduce the need to test numerous biocatalyst variants, saving R&D costs and decreasing the risk of process failure by identifying suitable enzymes earlier. Additionally, AI opens routes to molecules previously inaccessible to enzymatic conversion, creating new product opportunities.
The platform offers three specialized service modules. The first, AI-Driven Biocatalysis Solutions, provides an end-to-end workflow from target reaction analysis to scale-up characterization. It encompasses computational screening against sequence databases and proprietary libraries, process optimization across parameters like temperature, pH, solvent, substrate loading, and cofactor availability, and scale-up evaluation including expression yield and operational half-life. Quantitative data passes from each stage to the next, ensuring empirical evidence drives decisions. For moderately complex targets, this reduces the design-build-test-learn cycle from 12-24 months to 8-12 months.
The second module, AI-Driven Industrial Biocatalysis, bridges lab-scale performance and commercial production. It addresses substrate concentration optimization, cofactor regeneration, product inhibition management, immobilization and formulation development, integration of process analytical technology for real-time quality assurance, and delivery of complete technology transfer packages including SOPs and regulatory documentation. The goal is not just better enzymes but a fundamentally improved industrial workflow.
The third module, AI-Driven Green Biocatalysis, focuses on sustainability. Enzymatic reactions typically occur in aqueous media at room temperature, minimizing organic solvents and emissions. Mild conditions reduce heating and cooling needs, and enzymatic selectivity minimizes byproduct formation, simplifying purification and reducing waste. AI-guided development amplifies these advantages by identifying inherently more efficient enzymes, reducing the environmental footprint of both development and production.
The platform's capabilities were demonstrated in a recent case study on transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, exhibited high solubility and catalytic stability at 7-liter fermentation scale. These engineered enzymes convert prochiral ketones to sitagliptin, achieving enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production.
The impact of AI biocatalysis is most pronounced in pharmaceuticals, particularly for asymmetric synthesis of chiral intermediates and replacing hazardous reagents with cleaner routes. Agrochemicals and food industries are also adopting the technology to fine-tune toxicology profiles and deliver cleaner labels through enzymatic modification. Fine chemicals and personal care sectors are starting to explore high-value conversions and milder, more sustainable processes.
